TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00782418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: exenatide
Description: exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: exenatide
Description: exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
Study: NCT04004624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Cardiac Ablation
Study: NCT01416350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin - 250 mg every other day for 3 weeks
Description: Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
Study: NCT00814255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
Study: NCT03235596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
Study: NCT00444626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Gel Extra (DGE)
Description: Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Cream
Description: EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
Study: NCT00462020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 days of IV antibiotics (ceftriaxone and metronidazole)
Description: 5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Description: Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
Study: NCT00762619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Brush twice daily
Study: NCT03324152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - myositis
Description: 12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
Study: NCT00814255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril, losartan, and atorvastatin
Description: Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galactose
Description: galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
Study: NCT03324152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard low-intensity home exercise
Description: 12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
Study: NCT00471536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: 800 mg Given orally
Study: NCT01897961

Intervention type: OTHER
Group type: OTHER
Intervention: Anticorps anti-PLA2R1

Intervention type: OTHER
Group type: OTHER
Intervention: Anticorps anti-PLA2R1

Intervention type: OTHER
Group type: OTHER
Intervention: Anticorps anti-PLA2R1
Study: NCT01133431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
Description: From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
Study: NCT03324152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training (HIIT) - healthy
Description: 12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
Study: NCT01409408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 300 mg of aliskiren daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg daily for 8 weeks.
Study: NCT03820076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AZT-04
Description: Staphylococcus epidermidis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AZT-04
Description: Staphylococcus epidermidis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AZT-04
Description: Staphylococcus epidermidis
Study: NCT01123928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video and counseling for cataract patients
Description: Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
Study: NCT02212535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
Study: NCT04891887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education program
Description: Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study.
Study: NCT04021381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium and magnesium citrate
Description: Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
Study: NCT03393117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: 20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Controlled Analgesia Pump
Description: The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia Pump
Description: The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Narcotic
Description: Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Narcotic
Description: Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
Study: NCT01850017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
Study: NCT01810263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein supplement
Description: Dietary Supplement: high protein supplement
Study: NCT00612391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral minimally invasive approach (plate fixation)
Description: A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deltopectoral approach (plate fixation)
Description: Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
Study: NCT01196429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT01133431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
Description: From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 placebo tablet, Glimepiride 4 mg tablet
Description: From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
Study: NCT01196429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03585959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: superDimension™ Navigation System Version 7.2
Description: superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
Study: NCT02607020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercises in an self-management setting
Description: Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
Study: NCT00941720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: IV busulfan 0.8 mg/kg every 6 hours x 16 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
Study: NCT03209531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Pulse Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
Study: NCT03220113

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Lidocaine, Thiamine cohort
Description: Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
Study: NCT04624152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
Study: NCT00775606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir 400 mg/ritonavir 100 mg
Description: Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Study: NCT02774486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQP-AK-102
Description: IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
Study: NCT01196429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02572141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
Description: Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
Study: NCT01133431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 placebo tablet, Glimepiride 4 mg tablet
Description: From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
Study: NCT00679679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 750 mg BID for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diet counseling and exercise
Study: NCT05066828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two pieces obturator
Description: patient received two pieces obturator connecting by magnet attachment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: two pieces obturator
Description: patient received two pieces obturator connecting by magnet attachment
Study: NCT02630082

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Circumcision

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible sigmoidoscopy